'Angioprevention': Angiogenesis is a common and key target for cancer chemopreventive agents

FASEB Journal

Volumn 16, Issue 1, 2002, Pages 2-14

  Tosetti, Francesca ^a   Ferrari, Nicoletta ^a   De Flora, Silvio ^a,b   Albini, Adriana ^a,c  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c CENTRO DI BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

Antiangiogenesis; Chemoprevention; Flavonoids; NSAIDs; Protease inhibitors; Retinoids; Steroids; Thiols

Indexed keywords

ANGIOGENESIS INHIBITOR; EPIGALLOCATECHIN GALLATE; MATRIX METALLOPROTEINASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER CHEMOTHERAPY; CANCER PREVENTION; DRUG MECHANISM; HUMAN; MELANOMA; PRIORITY JOURNAL; REVIEW; TUMOR BLOOD FLOW;

ACETYLCYSTEINE; ANGIOGENESIS INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; CATECHIN; FLAVONOIDS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEASE INHIBITORS; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 0036136731     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.01-0300rev     Document Type: Review

References (158)

1. Isolation of a tumor factor responsible of angiogenesis
2. General mechanisms of metastasis
3. Clinical applications of angiogenic growth factors and their inhibitors
4. VEGF: An update on biological and therapeutic aspects
5. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
6. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
7. Perspectives on cancer chemoprevention research and drug development
8. Chemoprevention of cancer
9. Incipient angiogenesis
10. Recent advances in cancer chemoprevention, with emphasis on breast and colorectal cancer
11. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanism and implications for cancer growth and ulcer healing
12. 'Accidental' anti-angiogenic drugs. Anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples
13. Mechanisms of N-acetylcysteine in the prevention of DNA damage and cancer, with special reference to smoking related end-points
14. Tumor invasion: Molecular shears blunted by green tea
15. Signaling angiogenesis via p42/p44 MAP kinase cascade
16. The induction of cyclo-oxygenase-1 by a tobacco carcinogen in U937 human macrophages is correlated to the activation of NF-κB
17. Antioxidants reduce cyclooxygenase-2 expression, prostaglandin production, and proliferation in colorectal cancer cells
18. Inhibition of invasion, gelatinase activity, tumor take and metastasis of malignant cells by N-acetylcysteine
19. Proteases in invasion: Matrix metalloproteinases
20. N-Acetylcysteine inhibits endothelial cell invasion and angiogenesis while protecting from apoptosis
21. Role of basement membrane in tumor growth and metastasis
22. Induction of c-fos and c-jun proto-oncogene expression by asbestos is ameliorated by N-acetyl-L-cysteine in mesothelial cells
23. Intracellular glutathione levels regulate Fos/Jun induction and activation of glutathione S-transferase gene expression
24. Oncogenes and tumor angiogenesis: Differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts
25. 2 sensing
26. Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo
27. 2 in rat heart endothelial cells
28. Vascular endothelial growth factor (VEGF) and melanoma. N-acetylcysteine downregulates VEGF production in vitro
29. Certain aspects of molecular endocrinology that relate to the influence of dietary factors on the pathogenesis of prostate cancer
30. Protection against breast cancer with genistein: A component of soy
31. Inhibition of murine bladder tumorigenesis by soy isoflavones via alterations in the cell cycle, apoptosis, and angiogenesis
32. Genistein, a dietary-derived inhibitor of in vitro angiogenesis
33. Mechanisms of action of the soy isoflavone genistein: Emerging role for its effects via transforming growth factor beta signaling pathways
34. Genistein exerts multiple suppressive effects on human breast carcinoma cells
35. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia
36. Angiogenesis is increased in B cell chronic lymphocytic leukemia
37. Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor
38. Protease Inhibitors in oral carcinogenesis and chemoprevention
39. Progress in cancer chemoprevention: Development of dietderived chemopreventive agents
40. Anti-angiogenic potential of a cancer chemopreventive flavonoid antioxidant, silymarin: Inhibition of key attributes of vascular endothelial cells and angiogenic cytokine secretion by cancer epithelial cells
41. Significant inhibition by the flavonoid antioxidant silymarin against 12-O-tetradecanoylphorbol 13-acetate-caused modulation of antioxidant and inflammatory enzymes, and cyclooxygenase 2 and interleukin-1 alpha expression in SENCAR mouse epidermis: Implications in the prevention of stage I tumor promotion
42. Angiogenesis and prostate cancer: Identification of a molecular progression switch
43. Detrimental effect of cancer preventive phytochemicals sylimarin, genistein, and epigallocatechin3-gallate on epigenetic events in human prostate carcinoma DU145 cells
44. Antiangiogenic activity of prostate-specific antigen
45. Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen
46. Reduced risk of esophageal cancer associated with green tea consumption
47. Influence of drinking green tea on breast cancer malignancy among Japanese patients
48. Green-tea consumption and risk of stomach cancer: A population-based case-control study in Shanghai, China
49. Green tea and the risk of gastric cancer in Japan
50. Tea and tea polyphenols in cancer prevention
51. Comparative chemopreventive mechanisms of green tea, black tea and selected polyphenol extracts measured by in vitro bioassays
52. Why drinking green tea could prevent cancer
53. Angiogenesis inhibited by drinking tea
54. Tumor gelatinases and invasion inhibited by the green tea flavonol epigallocatechin-3-gallate
55. EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells
56. Ester bond containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo
57. Prevention of UVB-induced immunosuppression in mice by the green tea polyphenol(-)-epigallocatechin-3-gallate may be associated with alterations in IL-10 and IL-12 production
58. IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyteendothelial cell cross-talk
59. Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12
60. Inhibition of angiogenesis and induction of endothelial and tumor cell apoptosis by green tea in animal models of human high-grade non-Hodgkin's lymphoma
61. Cancer chemoprevention by tea polyphenols through mitotic signal transduction blockade
62. Suppression of extracellular signals and cell proliferation through EGF receptor binding by (-)-epigallocatechin gallate in human A431 epidermoid carcinoma cells
63. Epigallocathechin-3 gallate selectively inhibits the PDGF-BB-induced intracellular signaling transduction pathway in vascular smooth muscle cells and inhibits transformation of cis-transfected NIH 3T3 fibroblasts and human glioblastoma cells (A172)
64. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis
65. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis
66. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
67. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo
68. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors
69. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)
70. Singlet molecular oxygen ((1)O2): A possible effector of eukaryotic gene expression
71. Superoxide and hydrogen peroxide in relation to mammalian cell proliferation
72. Induction of in vitro angiogenesis in the endothelial-derived cell line, EA hy926, by ethanol is mediated through PKC and MAPK
73. Blockade of p38 mitogen-activated protein kinase pathway inhibits inducible nitric-oxide synthase expression in mouse astrocytes
74. Evidence that nitric oxide is an endogenous antiangiogenic mediator
75. Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer
76. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability
77. Advances in the development of retinoids as chemopreventive agents
78. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial
79. Inhibition of squamous cell carcinoma angiogenesis by direct interaction of retinoic acid with endothelial cells
80. Retinoic acid induces cells cultured from oral squamous cell carcinomas to become anti-angiogenic
81. Beta Interferon inhibits HIV-1 Tat-induced angiogenesis: Synergism with 13-cis retinoic acid
82. 3 and their combination inhibit angiogenesis induced by non-HPV-harboring tumor cell lines. RAR alpha mediates the antiangiogenic effect of retinoids
83. Synergistic effect of retinoids and interferon alpha on tumor-induced angiogenesis: Anti-angiogenic effect on HPV-harboring tumor-cell lines
84. Retinoids inhibit interleukin-12 production in macrophages through physical associations of retinoid X receptor and NFkappaB
85. Multiple regulatory elements in the murine stromelysin-3 promoter. Evidence for direct control by CCAAT/enhancer-binding protein beta and thyroid and retinoid receptors
86. Regulation of vascular endothelial growth factor expression in human keratinocytes by retinoids
87. Negative regulation of the rat stromelysin gene promoter by retinoic acid is mediated by an AP1 binding site
88. Nuclear hormone receptors inhibit matrix metalloproteinase (MMP) gene expression through diverse mechanisms
89. The AP-1 site and MMP gene regulation: What is all the fuss about?
90. Retinoid-mediated suppression of tumor invasion and matrix metalloproteinase synthesis
91. Effect of steroid hormones and retinoids on the formation of capillary-like tubular structures of human microvascular endothelial cells in fibrin matrices is related to urokinase expression
92. Effect of retinoic acid on the synthesis of tissue-type plasminogen activator and plasminogen activator inhibitor-1 in human endothelial cells
93. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin
94. Retinoids modulate endothelial cell production of matrix-degrading proteases and tissue inhibitors of metalloproteinases (TIMP)
95. Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells
96. Modulation of interferon action by retinoids. Induction of murine STAT1 gene expression by retinoic acid
97. Effect of the retinoid X receptor-selective ligand LGD1069 on mammary carcinoma after tamoxifen failure
98. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): An RXR-selective ligand
99. New oral chemotherapeutic agents for lung cancer
100. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer
101. Fenretinide and cancer prevention
102. Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide
103. In vitro effects of fenretinide on cell-matrix interactions
104. Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism
105. Integrins alpha(v)beta3 and alpha(v)beta5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide
106. Time course of fenretinide-induced modulation of circulating insulin-like growth factor (IGF)-I, IGF-II and IGFBP-3 in a bladder cancer chemoprevention trial
107. Identification of angiogenic properties of insulin-like growth factor II in in vitro angiogenesis models
108. Insulin and insulin-like growth factor-I induce vascular endothelial growth factor mRNA expression via different signaling pathways
109. Peroxisome proliferator-activated receptors: Roles in tumorigenesis and chemoprevention in human cancer
110. Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo
111. Endothelial cell apoptosis induced by peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy delta 12,14-prostaglandin J2
112. Peroxisome proliferator-activated receptor-gamma ligands inhibit choroidal neovascularization
113. 15-Dyeoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway
114. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase
115. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis
116. Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor
117. Pharmacological and endogenous progestins induce vascular endothelial growth factor expression in human breast cancer cells
118. 2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: Possible role for stress-activated protein kinase signaling pathway and Fas expression
119. 2-Methoxyestradiol blocks estrogen-induced rat pituitary tumor growth and tumor angiogenesis: Possible role of vascular endothelial growth factor
120. Hormonal carcinogenesis
121. Cancer Chemoprevention: Progress and promise
122. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue
123. Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: Evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts
124. Prostate cancer prevention trials in the USA
125. Hepatocyte growth factor and vitamin D cooperatively inhibit androgen-unresponsive prostate cancer cell lines
126. Role of mitochondria and caspases in vitamin D-mediated apoptosis of MCF-7 breast cancer cells
127. 3. Studies in cultured bovine aortic endothelial cells and human dermal capillaries
128. 3 inhibits angiogenesis in vitro and in vivo
129. Vitamin D inhibits angiogenesis in transgenic murine retinoblastoma
130. 3 receptor agonist
131. Chemopreventive agents: Protease inhibitors
132. Clinical modulation of oral leukoplakia and protease activity by Bowmn-Birke inhibitor concentrate in a Phase IIa chemoprevention trial
133. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer
134. Production of large amounts of hydrogen peroxide by human tumor cells
135. Involvement of the transcription factor NFκB in tubular morphogenesis of human microvascular endothelial cells by oxidative stress
136. Oxidants as stimulators of signal transduction
137. Oxidant signaling in vascular cell growth, death, and survival: A review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling
138. Activator protein 1 (AP-1)- and nuclear factor kappaB (NFkappaB)-dependent transcriptional events in carcinogenesis
139. Antioxidant and redox regulation of gene transcription
140. Suppression of nerve growth factor-induced neuronal differentiation of PC12 cells
141. Retinoic acid is a negative regulator of AP-1-responsive genes
142. 4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors
143. Induction of apoptosis by N-(4-hydroxyphenyl)retinamide and its association with reactive oxygen species, nuclear retinoic acid receptors, and apoptosis-related genes in human prostate carcinoma cells
144. Inhibition of activator protein 1 activity and neoplastic transformation by aspirin
145. Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin
146. Induction of interleukin-8 synthesis integrates effects on transcription and mRNA degradation from at least three different cytokine- or stressactivated signal transduction pathways
147. The AP-1 site is required for basal expression but is not necessary for TPA-response of the human stromelysin gene
148. Transcriptional inhibition of stromelysin by interferon-gamma in normal human fibroblasts is mediated by the AP-1 domain
149. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells
150. Thiol antioxidant, N-acetylcysteine, activates extracellular signal-regulated kinase signaling pathway in articular chondrocytes
151. Signal transduction events elicited by natural products: Role of MAPK and caspase pathways in homeostatic response and induction of apoptosis
152. 3 in normal human keratinocytes
153. p53 independent inhibition of proliferation and p21(WAF1/Cip1)-modulated induction of cell death by the antioxidants N-acetylcysteine and vitamin E
154. The antiangiogenic agent TNP-470 requires p53 and p21CIP/WAF for endothelial cell growth arrest
155. Growth factor-dependent induction of p21(CIP1) by the green tea polyphenol, epigallocatechin gallate
156. 3 in breast cancer cells
157. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer
158. Recent advances in chemoprevention of cancer